Researchers at MIT reported a novel lipid nanoparticle that dramatically enhanced mRNA vaccine potency in preclinical work, claiming the formulation could reduce required dose by up to 100‑fold. The team described particle engineering that improved delivery and expression, which could materially lower manufacturing costs and expand global vaccine availability if translated to humans. The paper emphasized preclinical results and noted further safety and translational work will be required.